Skip to main content

Table 2 Drug classes addressed in formalised consensus

From: Effects of an interprofessional Quality Circle-Deprescribing Module (QC-DeMo) in Swiss nursing homes: a randomised controlled trial

Therapeutic class (ATC code) Rationale for deprescribing a Number of NH (%)
n = 26 b
Proton-pump inhibitors (A02BC) Frequent overprescribing; side-effects in case of long-term use 21 (78%)
Lipid modifying agents (C10) Negative risk/benefit ratio in people aged 85 or more if used in primary prevention 17 (63%)
Benzodiazepines (N05B & N05C) Side effects in case of long-term use 10 (37%)
Urinary spasmolytics (G04BD) and anticholinergic drugs Lack of efficacy (urinary spasmolytics); frequent side effects (all anticholinergics) 9 (33%)
Glucose-lowering drugs (A10B) Higher HbA1C targets for very old patients; risk of adverse events if blood sugar too low 9 (33%)
Antihypertensives (C03, C07, C08, C09) Higher blood pressure targets for very old patients 8 (30%)
Bisphosphonates (M05BA & M05BB) Lack of evidence for efficacy after 5+ years of treatment 6 (22%)
Anti-dementia drugs (N06D) Lack of efficacy; high costs 6 (22%)
Antidepressants (N06A) Frequent overprescribing 6 (22%)
Antipsychotics (N05A) Lack of evidence for use in behavioural and psychological symptoms of dementia 5 (19%)
  1. ATC Anatomic Therapeutic Chemical classification, NH nursing home, HbA1C glycated haemoglobin; n (% of column); a: as presented in the education session; b: 1 NH did not perform the intervention